Why the study?
Acute STEMI remains a major cause of morbidity, mortality, and disability, necessitating a summary of recent advances in its treatment.
Answers are grounded in this paper and cite their sources.
This review reinforces that rapid transport for primary PCI with stent implantation, supported by modern antithrombotic agents, remains the optimal treatment strategy for STEMI.
PURPOSE OF REVIEW: Acute ST-elevation myocardial infarction (STEMI) is a major cause of morbidity, mortality, and disability. This review summarizes recent advances in the treatment of patients with STEMI. RECENT FINDINGS: The best prehospital and interhospital transfer strategy for patients with STEMI is rapid transport to a percutaneous coronary intervention (PCI) center by Emergency Medical Services, with prehospital diagnosis and activation of the cardiac catheterization laboratory. Coronary angiography is now recommended for all patients with STEMI. Advances in adjunctive pharmacological and device therapy have improved primary PCI results. Thrombus aspiration, drug-eluting stents, systemic hypothermia for survivors of cardiac arrest with anoxic encephalopathy, and stem cells as reparative therapy have undergone recent evaluation. SUMMARY: Primary PCI with stent implantation as soon as possible is the best treatment strategy for patients with STEMI. Aspirin, bivalirudin, and either prasugrel or ticagrelor are the best antithrombotic agents to support primary PCI. Thrombus aspiration and intra-aortic balloon counterpulsation are important device adjuncts. Systemic hypothermia appears to be an important advance for survivors of cardiac arrest with anoxic encephalopathy, but the benefits of stem cell therapy have yet to be proven.
No takes yet. Share an insight, caveat, or question.
Bates et al. (2012) conducted a review in Acute ST-elevation myocardial infarction (STEMI). Primary PCI with stent implantation was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: